Physician profile
Matthew C Wilson
NPI 1891726295
$112,362.05
in general payments reported to CMS, 2019-2025
24 companies · $15K in 2025
The $15K reported for 2025 was more than what 90% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,143 · 2020: $11K · 2021: $30K · 2022: $25K · 2023: $16K · 2024: $13K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Food and Beverage: $8,384 · Travel and Lodging: $976 · Education: $96.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,125.00 |
| Food and Beverage | $8,383.86 |
| Travel and Lodging | $975.95 |
| Education | $96.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $96,159.83 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $6,353.36 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $2,429.30 | 2019-2025 | Haegarda, Andembry, Kcentra |
| Regeneron Healthcare Solutions, INC. | $1,827.50 | 2019-2025 | Dupixent |
| Optinose US, INC. | $1,388.04 | 2019-2025 | |
| Pfizer INC. | $1,301.83 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $875.50 | 2020-2025 | |
| Genentech USA, INC. | $709.23 | 2019-2025 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.12 | 2019-2022 | |
| Genzyme Corporation | $335.05 | 2019-2025 | |
| Amgen INC. | $176.69 | 2022-2024 | Tezspire |
| Abbvie INC. | $84.08 | 2021-2022 | |
| Alk-Abello, INC | $79.00 | 2019-2023 | Ragwitek, Odactra, Grastek |
| Kaleo, INC. | $58.93 | 2019-2020 | |
| Galderma Laboratories, L.P. | $36.86 | 2024-2025 | Nemluvio |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $30.88 | 2020 | |
| Integra Lifesciences Corporation | $28.52 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Takeda Pharmaceuticals U.S.A., INC. | $26.13 | 2020 | |
| Paratek Pharmaceuticals, INC. | $25.74 | 2025 | Xhance |
| Incyte Corporation | $22.94 | 2022 | |
| Shire North American Group INC | $21.81 | 2019 | |
| Merck Sharp & Dohme LLC | $14.67 | 2019 | |
| Leo Pharma INC. | $14.48 | 2022 | |
| Convatec INC. | $13.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.